Bone metastases with their risk of SRE development and resulting impact on QoL, can become a clinically relevant problem in patients with lung adenocarcinoma and an EGFR mutation because of their prolonged post-bone metastases diagnosis survival [4,12,23,48,49]. Here, EGFR is linked to lung adenocarcinoma.